Initiation of Insulin Aspart in Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Registration Number
- NCT00572806
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in Europe. The aim of this trial is to investigate if using insulin aspart as start therapy will improve the efficacy on daytime blood glucose cycle profile in subjects with type 2 diabetes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
- Type 2 diabetes for at least 3 years
- HbA1c greater than 8.0%
- Body Mass Index (BMI) below 40.0 kg/m2
- Inadequate treatment with diet and OADs
- Never received treatment with insulin
Exclusion Criteria
- Type 1 diabetes
- Known or suspected allergy to investigational product
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Blood glucose value at 5 pm in a daytime blood glucose cycle profile
- Secondary Outcome Measures
Name Time Method HbA1c Hypoglycaemic episodes Evaluation of 24-hour blood glucose cycle
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie insulin aspart's efficacy in type 2 diabetes management?
How does insulin aspart compare to other rapid-acting insulins in controlling daytime hyperglycemia in type 2 diabetes?
Which biomarkers correlate with improved glycemic control following insulin aspart initiation in type 2 diabetes?
What adverse events are associated with early insulin aspart therapy in type 2 diabetes patients and how are they managed?
How do GLP-1 receptor agonists or SGLT2 inhibitors compare to insulin aspart as initial injectable therapies for type 2 diabetes?
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇫🇷MONTPELLIER cedex 5, France
Novo Nordisk Investigational Site🇫🇷MONTPELLIER cedex 5, France